Is There Still Time To Buy GlaxoSmithKline plc?

Can GlaxoSmithKline plc (LON: GSK) move higher, or are the company’s shares overvalued?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m looking at some of the most popular companies in the FTSE 100 and wider market to try and establish if there is still time for investors to buy in.

Today I’m looking at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) to ascertain if its share price has the potential to push higher.

Current market sentiment

The best place to start assessing whether or not Glaxo’s share price has the potential to push higher, is to take a look at the market’s current opinion towards the company.

gskUnfortunately at present, it would appear that the market is somewhat doubtful of Glaxo’s future plans as the company has suffered a number of setbacks during recent weeks. Specifically, during the past week alone, Glaxo has announced the withdrawal of a European Union application related to its ovarian cancer treatment Votrient, and company’s chronic coronary heart disease treatment, Darapladib failed to meet targets set in the treatment’s phase III trial. In addition, Glaxo has stopped testing its MAGE-A3ii cancer immunotherapeutic. These failures have left investors wondering what the future holds for Glaxo’s earnings growth potential.   

Additionally, Glaxo has come under scrutiny for allegedly bribing Chinese doctors for prescribing the company’s treatments. These allegations have had a dire effect on the company’s Chinese sales.

Upcoming catalysts

Even though Glaxo’s investors have been left wondering what’s next for the company after these recent failures, Glaxo’s investors still have plenty to look forward to.

Indeed, Glaxo still has numerous treatments under development, the most promising of which is the company’s experimental HIV protection drug. This new HIV treatment is already showing positive results in tests and has been described as “really promising”.

To compliment the development of new treatments, Glaxo is working on expanding overseas, recently acquiring an additional holding in the company’s Indian and Indonesian consumer healthcare units. Further, Glaxo’s management has stated that the company will invest £130m within Sub Saharan Africa over the next five years to increase capacity and build the foundations for long-term growth.   


Surprisingly, despite recent disappointments Glaxo’s shares currently trade at a high valuation, in comparison to the company’s historic average. Specifically, Glaxo’s shares currently trade at a forward P/E of 15.5, above the company’s ten-year average P/E of just under 11. What’s more, City analysts currently predict that Glaxo’s earnings will fall during 2014, which makes the company look expensive when taking into account falling earnings. 

That said, after factoring in Glaxo’s defensive nature and the company’s juicy 5% dividend yield I seems as if Glaxo’s shares are worth this high valuation. 

Foolish summary

So overall, I feel that there is still time to buy GlaxoSmithKline at current levels

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in GlaxoSmithKline. 

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

Is this FTSE 100 passive income superstar also its best bargain right now?

This FTSE 100 gem still looks to me like one of the best bargains in the index. It appears very…

Read more »

Investing Articles

If I’d put £10,000 into Meta stock at the start of 2024, here’s what I’d have now

Our writer looks at the year-to-date performance of Meta stock and considers whether he'd consider buying this magnificent tech share.

Read more »

Hand arranging wood block stacking as step stair on paper pink background
Investing Articles

Investing £5 a day in this dividend giant can make me a £14,067 annual second income!

This FTSE 100 high-yield star can make me a major second income, supported by a strong business outlook and an…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Taylor Wimpey shares yield a fabulous 6.41%, but is the dividend safe?

Harvey Jones has enjoyed plenty of growth and income after buying Taylor Wimpey shares last year. But is today's high…

Read more »

Yellow number one sitting on blue background
Investing Articles

1 FTSE lithium stock I think could be ready to rocket

Jon Smith explains why the lithium price could be due a rally, and why shares of one related FTSE stock…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
US Stock

This growth stock that Warren Buffett owns just hit 52-week lows. Should I buy?

Jon Smith flags up a high-profile US stock that the great Warren Buffett bought back in 2020 but which has…

Read more »

White female supervisor working at an oil rig
Investing Articles

Could the UK general election be bad news for this FTSE 250 energy producer?

The country is due to vote in the general election on 4 July. Our writer looks at the possible implications…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should we buy cheap FTSE 100 shares now, before it’s too late?

The FTSE 100 is up 5% so far in 2024 and hit an all-time high in May. That means the…

Read more »